Gelatinous Capsules of β-Lapachone for Anti-cancer Therapies

被引:0
|
作者
Presmich, Geisiane M. A. [1 ]
Rolim, Larissa A. [1 ]
Medeiros, Flavia P. M. [1 ,3 ]
Albuquerque, Miracy M. [2 ]
Rolim-Neto, Pedro J. [1 ]
机构
[1] Univ Fed Pernambuco, Lab Tecnol Medicamentos, Dept Ciencias Farmaceut, BR-50740521 Recife, PE, Brazil
[2] Univ Fed Pernambuco, NCQMC, BR-50740521 Recife, PE, Brazil
[3] Lab Farmaceut Estado Pernantbuco LAFEPE Largo de, BR-52171010 Recife, PE, Brazil
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2010年 / 29卷 / 05期
关键词
beta-lapachone; soft gelatinous capsules and hard; stability; PROSTATE-CANCER CELLS; MEDIATED APOPTOSIS; DERIVATIVES; INHIBITION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
"Gelatinous Capsules of beta-Lapachone for Anti-cancer Therapies". beta-lapachone is a natural ortonaftoquinona of ipe purple growing mainly in Brazil, also obtained by the process of semi-synthesis of its isomer lapachol. It is a simple plant product that has demonstrated excellent potential in antineoplastic studies in albino rats, mice and cell cultures. Works by a particular mechanism of apoptosis against various types of cancer, especially some strains of prostate refractory to conventional treatments. It has low solubility in water, the development of a pharmaceutical form the basis of beta-lapachone providing favorable bioavailability is a key point for the continuity of research with this asset. Hard gelatine capsules containing 250 mg of beta-lapachone and soft gelatine capsules containing 30 mg beta-lapachone were developed. Due to the crystalline form and character of lipophilic beta-lapachone, the hard gelatin capsules did not show acceptable levels of dissolution, however, the soft gelatinous capsules showed satisfactory results for continuation of studies in this active.
引用
收藏
页码:674 / 680
页数:7
相关论文
共 50 条
  • [1] Targeted anti-cancer therapies for renal cancer
    Amato, Robert J.
    Jac, Jaroslaw
    DRUGS, 2006, 66 (17) : 2161 - 2171
  • [2] Targeted Anti-Cancer Therapies for Renal Cancer
    Robert J. Amato
    Jaroslaw Jac
    Drugs, 2006, 66 : 2161 - 2171
  • [3] Use of bacteria in anti-cancer therapies
    Ryan, RM
    Green, J
    Lewis, CE
    BIOESSAYS, 2006, 28 (01) : 84 - 94
  • [4] Cancer immunology - development of novel anti-cancer therapies
    Rothschild, Sacha I.
    Thommen, Daniela S.
    Moersig, Wolfgang
    Mueller, Philipp
    Zippelius, Alfred
    SWISS MEDICAL WEEKLY, 2015, 145
  • [5] Genotype Driven Anti-Cancer Therapies for Colon Cancer
    Mockus, Susan
    Stafford, Grace
    Potter, Christopher
    Ananda, Guruprasad
    Hinerfeld, Douglas
    Tsongalis, Gregory
    MODERN PATHOLOGY, 2015, 28 : 180A - 180A
  • [6] Genotype Driven Anti-Cancer Therapies for Colon Cancer
    Mockus, Susan
    Stafford, Grace
    Potter, Christopher
    Ananda, Guruprasad
    Hinerfeld, Douglas
    Tsongalis, Gregory
    LABORATORY INVESTIGATION, 2015, 95 : 180A - 180A
  • [7] Anti-cancer therapies targeting the tumor stroma
    Valeska Hofmeister
    David Schrama
    Jürgen C. Becker
    Cancer Immunology, Immunotherapy, 2008, 57 : 1 - 17
  • [8] Nuclear assembly as a target for anti-cancer therapies
    Gorjanacz, Matyas
    NUCLEUS, 2014, 5 (01) : 47 - 55
  • [9] Skin Malignancies Due to Anti-Cancer Therapies
    Starace, Michela
    Rapparini, Luca
    Cedirian, Stephano
    CANCERS, 2024, 16 (11)
  • [10] Listeria monocytogenes as a Vector for Anti-Cancer Therapies
    Tangney, Mark
    Gahan, Cormac G. M.
    CURRENT GENE THERAPY, 2010, 10 (01) : 46 - 55